40 results on '"Gerber, Jonathan A"'
Search Results
2. Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation
3. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
4. The Prevalence of Müllerian Anomalies in Women with a Diagnosed Renal Anomaly
5. Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses
6. A User’s Guide to Novel Therapies for Acute Myeloid Leukemia
7. Preoperative Predictors of Pathological Lymph Node Metastasis in Patients with Renal Cell Carcinoma Undergoing Retroperitoneal Lymph Node Dissection
8. Prognostic Discrimination within a Heterogeneous Population of TP53-Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia
9. Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics
10. A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemia
11. Circulating clonotypic B cells in classic Hodgkin lymphoma
12. Clonal Dynamics and Deterministic Clinical Fate Mapping of Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukemia with TP53 Disruption
13. BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
14. Early Identification of TP53 mutation in Myelodysplastic Neoplasms and Acute Myeloid Leukemia Via Point-of-Care p53 Immunohistochemistry
15. Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis
16. Myeloid Derived Suppressor Cells and Their Potential Impact on Minimal Residual Disease Status and Disease Response in a Cohort of Patients with Plasma Cell Dyscrasias
17. Impaired Clearance of DNMT3A/TET2/ASXL1-Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia
18. Novel abdomino-pelvic anomalies in Kagami-Ogata syndrome
19. 516 - Low Dose Cytoxan Mobilization – a Single Institution Experience
20. 260 - Retrospective Single Institution Comparative Study of Outcomes after Post-Transplant Cyclophosphamide for Haploidentical, Matched Unrelated, Mismatched Unrelated and Matched Sibling PB HSCT
21. Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation
22. Clinico-Genomic Profiling and Clonal Dynamic Modeling of Spliceosome-Mutant Myelodysplastic Syndrome and Acute Myeloid Leukemia
23. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy
24. Thoracic t(9;22)-Positive Granulocytic Sarcoma as Initial Presentation of Chronic Myeloid Leukemia
25. Patient Reported Financial Toxicity in Acute Leukemia
26. Survival and Time to Response with Frontline Hypomethylating Agents in AML
27. MP50-03 EMERGENCY ROOM UTILIZATION AND ASSOCIATED COSTS FOR PEDIATRIC VS. ADULT NEPHROLITHIASIS
28. Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths
29. Aldehyde Dehydrogenase Activity in the Leukemic Stem Cell Compartment Uncovers Opposing Methylation Patterns of Leukemia Stem Cells in AML
30. Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program
31. A Novel Approach to Identify a Putative Leukemia Stem Cell Population in Acute Lymphocytic Leukemia (ALL) and Distinguish Philadelphia Chromosome-Positive ALL from Lymphoid Blast Crisis Chronic Myeloid Leukemia
32. A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States
33. The JAK2V617F Stem Cell Burden Is Mosaic, Dynamic and Correlates with Clinical Disease Burden in the MPN: An Exploitable Target
34. Next-Generation Bisulfite Sequencing of Aml Reveals Widespread Acquisition of Epigenetic Abnormalities in Leukemic Stem Cells That Are Stably Retained in More Mature Leukemic Cell Fractions
35. Congenital Neutrophilia Arising from a T618I Germline Mutation in the CSF3R Gene
36. Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy: Do They Matter?
37. Polycythemia Vera: Redefinition in the Genomic Era
38. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)
39. The Leukemic Stem Cell in Polycythemia Vera and Primary Myelofibrosis Is Distinct From the Initiating JAK2 V617F-Positive Hematopoiertic Stem Cell
40. The Clinical Relevance of Acute Myeloid Leukemia Stem Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.